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1.1. Natural Product for Lead Identification. 
 
      The directory of bioactive natural products started more than 100 
years ago. They are usually identified as chemical compounds 
isolated/derived from natural sources i.e. living organisms such as plants, 
animals and microorganisms. (1) Chemistry of natural products is related 
to the isolation, biosynthesis and structure elucidation of new products 
that led to a new medical and crop protection agents. Due to their 
chemical diversity and various activities against diseases, they have been 
playing an important role in pharmaceutical and agricultural research. (2)  
      The World Health Organization (WHO) estimated that 80% of the 
earth inhabitants mainly depend on traditional medicines for their health 
care. (3) Plants have been the roots of the traditional medicine that has 
existed for thousands of years starting from the first records about 2600 
BC. Some of these plants are still in use today for the treatment of 
ailments ranging from coughs and colds to parasitic infections and 
inflammation. (4) Oceans host 32 out of the discovered 35 phyla of life on 
earth, and appear to cover about 71% of earth surface (Fig. 1) the 
diversity of species per unit area is as high as 1000 species per square 
meter in the Indo-pacific Ocean with the highest species diversity being 
in coral reefs. (5) Therefore it is not surprising that oceans are considered 
as vast untapped reservoirs of highly diverse and unique natural products. 
So far over 14,000 new biologically active compounds have been 
identified from marine sources.    
      Approximately 30 % of the drugs in the market worldwide are natural 






Fig. 1. Marine environment. 
 
      Natural products show a diversity of chemical structures that are not 
accessible even by the most sophisticated synthetic concepts. Moreover, 
natural products have often opened up completely new therapeutic 
approaches. They have contributed for identifying and understanding 
novel biochemical pathways and proved to make not only valuable drugs 
available but also essential tools in biochemistry and molecular cell 
biology. (6) Natural product sources are basically of two types. Firstly; the 
terrestrial source which includes plants, animals, and microorganisms, 
secondly; the marine source which focuses mainly on invertebrates. From 
the taxonomic consideration, marine organisms are significantly more 
diverse than terrestrial organisms. Furthermore, in contrast to animals 
from terrestrial habitats, invertebrates from marine environment are rich 
sources of complex natural products derived from numerous biosynthetic 
pathways. (7) 
 
1.1.1. Current Status of Marine Natural Products Research. 
      As we mentioned before the ocean covers about 71 % of the earth 
surface providing a diverse living environment for invertebrates. (8) 
Therefore, marine natural products will play a major role in drug 




years ago when Bergmann discovered the novel bioactive arabino-
nucleoside from the marine sponge Cryptotethya crypta. (9) This discovery 
encouraged natural products chemists to pay their attention to marine 
natural products as important biomedical sources.  
 
 1.1.2. Marine Organisms as a Source of New and Biologically Active 
Metabolites. 
      The marine environment comprises 71 % of the earth’s surface, and 
consists of extreme and contrasting habitats, ranging from tropical reefs 
to ice-shelf of the polar seas, and to black smokers in the deep sea. The 
biodiversity in the world’s oceans is immense, as example a 35 known 
animal phyla 15 are exclusively marine, and 32 of them have marine 
representatives. (10) Some habitats are known to be particularly numerous 
in species, e.g., tropical marine reefs, which represent one of the most 
diverse ecosystems encountered on the earth, comparable in diversity to 
tropical rain forests. Nearly all forms of marine life have attracted the 
attention of natural products chemists, with reports about secondary 
metabolites from sponges dominating by number. (11) Marine natural 
products are distinguished by a great chemical diversity. Metabolites 
from nearly all groups of natural products have been discovered. 
Halogenated compounds are particularly numerous due to the natural 
abundance of chlorine, bromine and to a lesser extent iodine in sea water. 
(12) The annual reviews on marine natural products by Faulkner 1998, and 
previous reviews, (13) and the database MARIN LIT Blunt & Munro, 1999 
(14) provide an overview of the impressive variety of the compounds 
encountered. Some of these compounds clearly serve an ecological 
purpose. A detailed survey of literature for laboratory feeding assay with 




sponges contained metabolites which deterred feeding by the wrasse 
Thalassoma bifasciatum. (15) Natural products are also involved in the 
competition for the limited space on coral reefs. Its reported that 
Plocamium hamatum,s metabolites (chloromertensene) has been shown to 
induce necrosis in soft coral Sinularia cruciata at direct contact, which 
led to many observed effects. (16) 
 
1.1.3. Metabolites with Prominent Pharmacological Activities – 
Example Halichondrin B. 
      The reported metabolites from marine organisms are not only 
interesting from an ecological or chemical point of view, but also some of 
them have been shown to possess prominent pharmacological activities, 
e.g., bryostatins, (17) didemnins (18) and ecteinascidins. (19) These findings, 
and the fact that some of these metabolites belong to unique structural 
types brought them into the focus of the pharmaceutical industry. A small 
number of compounds are currently being evaluated in clinical trials; 
many of them as antitumor agents. (20) The supply of sufficient amounts 
of compounds for pharmaceutical development is often problematic. This 
issue will be discussed using the example of halichondrin B, an 
antineoplastic compound currently in preclinical evaluation. Halichondrin 
B was first isolated from the sponge Halichondria okadai as the most 
potent member of a series of related antitumor compounds. (21) Later on, it 
was also reported from other sponge species including Phakellia carteri 
(22) and Lissodendoryx sp. (23) the absolute stereochemistry was deduced 
from comparisons with the related compound, norhalichondrin A, the 
structure of which had been established by X-ray crystallographic 
analysis of its p-bromophenacyl ester. (24) Halichondrin B showed in vitro 




and it had a significant activity in vivo against B-16, P-388 and L-1210 
tumours in mice. (24) Mechanism of action studies at the NCI revealed it 
to bind to the vinca domain of tubulin, and to arrest cells in mitosis. (25) In 
the same study, it could be shown to inhibit the in vitro polymerisation of 
purified tubulin, and the microtubule assembly. Such mechanism of 
action studies, and even more in vivo experiments and future clinical 































Its natural content in sponges ranges from 10-5–10-6 %. Mass collection of 
biomass is thus not very effective, if ever applicable, and may have 
massive ecological impacts, even leading to the extinction of a population 
or species. A total synthesis of halichondrin B has been reported, (26) but 
probably involves too many steps for being an economically valid 
alternative. Thus, to obtain further amounts of halichondrin B for clinical 
trials a large-scale culture of the macroorganism, i.e. the sponge 
Lissodendoryx sp., has been established. (27) This is the first example of 
mass cultivation of sponge species for pharmaceutical purposes. A further 
possibility to obtain sufficient amounts of a selected compound vividly 
discussed in the scientific community is the discovery of a microorganism 




suspected to be the true biosynthetic producers of metabolites isolated 
from marine macroorganisms. This is especially likely, if the compound 
in question has been obtained from various macroorganisms not closely 
related taxonomically, and if the compound belongs to a structural type 
already known from microorganisms. Although halichondrin B has been 
found in several sponge species from different origins, and its structure 
resembles that of polyethers known from dinoflagelates, to date there is 
no direct evidence for the contribution of microorganism to its 
biosynthesis. (27) 
  
 1.2. Marine Microorganisms. 
      The example of halichondrin B demonstrates that some marine 
natural products have such complex structures, that the only reasonable 
supply is their isolation from the producing organism. Organisms that 
could easily be cultured in large amounts would thus be ideal. Such 
organisms might be marine microorganisms. The fact that some marine 
microorganisms are easily cultured and that they had long been neglected 
by many marine natural product chemists, has led to an increased 
research effort in this area during the last 10 years. Research is focusing 
mainly on marine bacteria, fungi and microalgae as reflected by the 
number of natural products described from each group of organisms. (13, 
14) 
 
1.2.1 Marine Bacteria as a Source for Natural Products.  
      The oceans are massively complex and consist of diverse assemblages 
of life forms. The water column of the oceans contains approximately 106 
bacterial cells per ml. (28) Marine bacteria and other marine 
microorganisms develop unique metabolic and physiological capabilities. 




produce compounds that might not be produced by their terrestrial 
counterparts. Since 1990, the number of bioactive metabolites from 
marine bacteria has exponentially increased. (29-41)  
      The search for new bioactive chemicals from marine organisms 
resulted in the isolation of about 10000 metabolites, (42) many of which 
are potential biomedical. These agents show a broad spectrum of 
biological activities. Up to now, bioactive agents were isolated 
extensively from Streptomyces, Altermonas/Pseudoalteromonas, Bacillus, 
Vibrio, Pseudomonas, and Cytophaga. These microorganisms were 
isolated from seawater, sediments, algae and marine invertebrates. They 
are able to produce quinones, polyenes, macrolides, alkaloids, peptides 
and to a lesser extent terpenoids. Some of the first marine metabolites 
were isolated from seawater bacteria. The highly brominated pyrrole 
antibiotic (pentabromopseudiline) was active against Gram-positive 
bacteria. Its biosynthesis was not apparent from its structure, which led to 
studies by Laatsch and co-workers with Alteromonas luteoviolaceus on 
the biosynthesis (43) as well as on the structure-activity relationships. (44)  
      The pioneering work of Okami and co-workers represents the first 
building unit in the knowledge of the chemistry of marine derived 
bacteria, in particular of Actinomycetes. They have reported the isolation 
of a benzanthraquinone antibiotic from the actinomycete Chainia 
purpurogena (45) and istmycins A and B (1a and 1b) antibiotics from the 
Streptomyces tenjimariensis. One of the early marine metabolites is the 2, 
3-indolinedione (isatin, 2). This compound is produced by a bacterium 
colonizing the surface of the embryos of the shrimp Palaemon 
macrodactylus and protects the eggs against the pathogen fungus 




      A new macrolide with antibacterial, antiviral and cytotoxic activities 
was isolated from a deep sea unidentified unicellular bacterium, 
macrolactin A (3). (46) Two bicyclicdepsipeptides, salinamide A and B (4a 
and 4b) were isolated from Streptomyces sp. from the surface of the 
jellyfish Cassiopeia xamachana. They exhibited moderate antibiotic 
activity, but were potent topical anti-inflammatory in chemically induced 








R1=H, R2=NH2 istamycin A (1a)































A= salinamide A (4a)




Fig. 2. Structures of istamycins A and B (1a and 1b), isatin (2), 





1.2.3. Newly Described Metabolites from Marine Bacteria. 
      Since  the  beginning  of  this  century  a large number of   marine  
compounds  have  been described.  Interestingly,  within  the  same  
period  the  number  of  described  metabolites produced  by  terrestrial  
bacteria  does  not  exceed  150  compounds. (49) Nearly  100  marine  
compounds  from  bacterial  origin  were  isolated  within  the  year  
2004. Actinomycetes were as usual the most studied group.  A  novel  
bioactive  macrolide  was isolated  from  the  culture  of  the  
Micromonospora  sp. IB-96212 (5). (50)  
      The group of Laatsch isolated novel anticancer compounds, 
chandrananimycins A, B and C (6a, 6b and 9); from Actinomadura sp. (51) 
these compounds exhibited antibacterial and cytotoxic activities. A 
bactericidal antibiotic, MC21-A (3, 3´, 5, 5´-tetrabromo-2, 2´-
biphenyldiol, (11) was isolated from the new species Pseudoalteromonas 
phenolica. It is a brominated anti-MRSA substance that rapidly 
permeabilizes the cell membranes of MRSA, but it has no lytic activity 
against bacterial cells or human erythrocytes. (52) Recently, 
mechercharmycin A (7) and mechercharmycin B (8) were isolated the 
bacterium Thermoactinomyces sp. X-ray crystallographic analysis of 
these compounds showed that mechercharmycin A is a cyclic-peptide and 
mechercharmycin B is its linear congener. Mechercharmycin A showed 
cytotoxic activity against human lung carcinoma and human leukaemia. 
(53) The isolation of highly cytotoxic proteasome inhibitor, 
salinosporamide A (10), from Salinospora sp. represents one of the 
remarkable studies in this century. This new genus was proposed by 
Fenical and his colleagues in 2002 to a group of rare obligate marine 
actinomycetes isolated from the ocean sediments. (54) This compound 




carcinoma. This effect was due to the inhibition of the 20S proteasome. 
(55) Recently halogenated macrolides, sporolides A and B (12a and 12b) 
were isolated from Salinospora tropica. Sporolides A and B were neither 
antibacterial nor cytotoxic (Fig. 3). (56) Despite this interest on metabolites 
from marine derived bacteria, studies in this field encounter some 
problems. Firstly, not more than 5% of the marine bacteria observed in 
marine samples are amenable to be cultured with the normal 
microbiological techniques. (57) Secondly, the taxonomy of marine 
bacteria is very poorly defined and many publications describe 
compounds isolated from numbered strains of otherwise partially or 
totally unidentified bacteria. Thirdly, very low fermentation yields that 
may be in some cases in the range of mg/L from dense culture are 






























R1= OH, R2= COCH3 chandrananimycin A    (6a)












































































R1= Cl, R2=H sporolide A (12a)






Fig. 3. Structures of macrolide IB-96212 (5), chandrananimycins A and B 
(6a and 6b), chandrananimycin C (9), antibiotic MC21-A (11), 
mechercharmycin A (7), mechercharmycin B (8), salinosporamide A (10) 







1.3. Significance of the Study. 
1. Lead identification is an important part of the drug discovery process. 
This increases the diversity of active prototype molecules, which can be 
candidates for new drugs. Terrestrial and marine environments are 
challenging sources of a variety of novel biologically and 
pharmacologically active compounds. 
2. Marine microorganism is a rich source of biologically active secondary 
metabolites. The biosynthesis of secondary metabolites by this 
microorganism has been speculated as a result of their physical and 
biochemical adaptation to their environment. In the last two decades, 
many new compounds were isolated from these organisms and have been 
promoted as candidates for the development of new drugs, especially as 
anticancer drugs. There is therefore, a need to continue research for 
discovery of novel secondary metabolites from marine invertebrates. 
3. Marine metabolites have a wide application not only for 
pharmaceutical purposes but also for biological tools. Hence, there is a 
need for a continuous intensive research in marine natural products 
chemistry. 
 
1. 4. Aim of the Study. 
The aim of this research is to isolate and structurally elucidate 
biologically active secondary metabolites from marine microorganisms. 
 
1.5. Scope of the Present Study. 
1. Isolation of Bacteria from Marine Sponges and Other Collected 
Samples. 
      This part of the work aimed at finding a suitable isolation method for 
obtaining bacteria in a great taxonomic variety from marine samples. For 




adapted strains, and to exclude terrestrial contaminants of chemically 
well-investigated genera. The isolated bacteria then were to be identified 
taxonomically in order to select promising strains for biological screening 
and chemical investigations. 
 
2. Biological and Chemical Screening of Bacterial Extracts. 
      The selected strains had to be small scale cultured in order to obtain 
amounts of extracts suitable for the biological tests. These tests mainly 
consisted of disc diffusion assays for antibacterial and antifungal. They 
aimed at estimating the potential of the isolated bacteria to produce 
biologically active metabolites, and served for the selection of strains for 
chemical investigations. 
 
3. Chemical Investigations of Selected Bacterial Strains.  
      The main purpose of the chemical investigations was to isolate pure 
and biologically active metabolites from bacterial culture extracts. To 
achieve this, selected strains had to be cultured on a large-scale, extracted, 
and the extracts separated using diverse chromatographic methods, 
mainly HPLC. In order to identify biologically active compounds, a bio-
assay guided isolation was attempted. The chemical investigations were 
completed by structure elucidation and physical characterizations of the 
isolated metabolites. 
  
4. Biological Evaluation of Isolated Pure Compounds. 
      Natural products may serve as lead structures for new 
pharmaceuticals. Thus, any pure compound obtained in this study was 
evaluated in a diverse set of bio-assays. This included the same assays as 





2. Results and Discussion. 
2.1. Chemical Investigation of the Culture Broth of Staphylococcus sp. 
(No. P-100826-4-6).  
      As a part of ongoing effort to discover biologically active metabolites 
from marine bacteria, Staphylococcus sp. (No. P-100826-4-6) was 
selected from our screening program for further studies. It has been 
observed that culture broth of Staphylococcus sp. (No. P-100826-4-6) 
derived from Corallina officinalis Linneaus family Corallinaceae, showed 
antifungal activity against Aspergillus niger, Penicillium crustosum and 
Schizophyllum commune. Therefore, we have researched the active 
constituents of this bacterium.  
      The marine bacterium Staphylococcus sp. was obtained from 
Corallina officinalis Linneaus family Corallinaceae, collected in 
Nagasaki Shitsu coast of Japan in 2010. The strain was cultured at 25 ºC 
on rotary shakers using a seawater-based medium. The fermentation broth 
(32L) was successively partitioned with EtOAc to give EtOAc extract 
(5.2 g) and the aqueous layer was subjected to Diaion HP-20 using H2O, 
60% MeOH, 100% MeOH and acetone to give 60% MeOH (28.3 g), 
100% MeOH (8 g) and acetone (3.9 g) fractions respectively (Scheme A). 
  
2.1.1. Extraction, Fractionation and Isolation of the Constituents of 
the Culture Broth of Staphylococcus sp. (No. P-100826-4-6). 
The EtOAc extract and 100% MeOH fraction showed antifungal activity 
against the fungi stated above (Table 1). The EtOAc extract and 100% 
MeOH fraction were subjected to Sephadex LH-20, silica gel column 
chromatography and octadecylsilyl (ODS) column chromatography 




(4), (9), and (10), have been isolated along with fifteen known 
compounds: cyclo (-L-pro-L-val-) (1), (58) bacillusamide B (2),(59) indole-
3-carboxylic acid (5), (60) 1,3-dideoxy-3-C-methyl arabinitol (6), (61) 
thymine (7), (62) uracil (8), (61) (-L-pro-L-leu-) (11), (63) cyclo (-L-pro-L-phe-
) (12), (64)  cyclo (-L-pro-D-phe-) (13), (65) cyclo (-D-6-Hypro-L-phe-) (14), 
(66), cyclo (-L-pro-L-tyr-) (15), (67) macrolactin B (16), (68) cyclo, cyclo (-L-
pro-L-ala-) (17), (69) L-phenylalanine (18), (70) and L-tryptophan (19) (71) 
(Fig. 4, 5 and 6). The structures of these compounds were elucidated by 
using extensive spectroscopic methods. 
 
Scheme (A): Extraction, fractionation of the culture broth of 
Staphylococcus sp. No (p-100826-4-6). 
 








 H2O, 60% MeOH
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Table 1: Biological activities of extract and fractions of culture broth of    
Staphylococcus sp.  (No. P-100826-4-6). 
 
Antimicrobial activity test (125µg/disc) 
Microbial strains EtOAc 60% MeOH 100% MeOH Acetone 
Bacillus subtillis  ‒ + ‒ ‒ 
Staphylococcus aureus  ‒ ± ‒ ‒ 
Serratia marcescens  ‒ ‒ ‒ ‒ 
Escherichia coli ‒ ‒ ‒ ‒ 
Pseudomonas aeruginosa ‒ ‒ ‒ ‒ 
Schizophyllum commune ++ ‒ ++ ++ 
Vivrio parahaemorytics ‒ ‒ ‒ ‒ 
Aspergillus niger ++ ‒ ++ ‒ 
Penicillium crustosum + ‒ ++ ‒ 
Candida albicans ‒ ‒ ‒ ‒ 
Saccharomyces cerevisae ‒ ‒ ‒ ‒ 
Trichophyton concentricum ‒ ‒ ‒ ‒ 
Inhibition circle: －; < 8 mm, ±; 8 mm, ＋; < 8mm ~ < 10 mm, ++; ≧ 10 mm 
Scheme (B):  Isolation of the main constituents from EtOAc extract of 
the culture broth of Staphylococcus sp. (No. P-100826-4-6) (charts 2 ~ 6). 
 
Silica gel C. C. 
(n-hexane - acetone = 10:0 ~ 0:10)











    (380 mg)
Fr.1
Silica gel C. C. (CHCl3 - MeOH = 10:0 ~ 0:10)


















  Silica gel C. C. (n-hexane - acetone = 10:0 ~ 0:10,
 acetone - MeOH  = 5:5: ~ 0:1)
Fr.13-4-2
(176 mg) Fr.13-4-3  (5 mg)
Fr.13-4-4
  (70 mg)
Fr.13-4-1
(40 mg)
 Silica gel C. C.
 (CHCl3 - MeOH = 99:1)
Fr.13-4-3-1 Fr.13-4-3-3 Fr.13-4-3-4Fr.13-4-3-2
(30 mg) (10 mg) (15 mg) (10 mg)
Purified on Sephadex LH-20
(CHCl3 - MeOH  = 1:1)
Fr.13-4-3-2
Compound 2 (10 mg)
HPLC, Wakosil 5C-18,
 (40%MeOH)
     Fr.
13-4-3-1-1
      Fr.
13-4-3-1-2
    Fr.
13-4-3-1-3
    Fr.
13-4-3-1-4
     Fr.
13-4-3-1-5
     Fr.
13-4-3-1-6
    Fr.
13-4-3-1-7
      Fr.
13-4-3-1-8
(3.25 mg) (2.25 mg) (2.3 mg) (2.35 mg) (2.26 mg) (1.7 mg) (5 mg) (3.8 mg)




(CHCl3 - MeOH = 5:5)
Fr.15 (96 mg)
Fr.15-1 Fr.15-2
(24 mg) (15 mg)


























HPLC, Develosil C-30, 
(55% MeOH)










(CHCl3 - MeOH = 1:1)
Compound 6 (86 mg)
Fr.18-3-2Fr.18-3-1
(8 mg) (6 mg)
Compound 7 (8 mg)
 
Chart 5 















Compound 8 (31 mg)
Silica gel C.C.
(n-hexane - acetone = 6:4)
 ODS Column, (70% MeOH)
Fr.20-1-2-1 Fr.20-1-2-2 Fr.20-1-2-3 Fr.20-1-2-4 Fr.20-1-2-5











 Scheme (C):  Isolation of the main constituents from 100% MeOH    
 fraction of the culture broth of Staphylococcus sp. (No. P-100826-4-6)   
                                            (charts 7 ~ 9). 
 
 
MeOH Fraction (8 g)
Dissolved in mixture of
(CHCl3 - MeOH - H2O =  5:5:1)
Soluble part
   (  4.7 g)
Insoluble part
     (2.3 g)
Sephadex LH-20 
(CHCl3 - MeOH = 1:1)
Fr.1 Fr.2 Fr.4 Fr.6 Fr.7Fr.5Fr.3
(1.3 g) (1.7 g) ( 753 mg) (587 mg) (465 mg) (138 mg) (127 mg)
ODS Column, 
(H2O - MeOH = 8:2 ~ 0:10)
Fr. 4-1 Fr.4-2 Fr.4-3 Fr.4-4 Fr.4-5 Fr.4-6 Fr.4-7
(45 mg) (70 mg) (105 mg) (45 mg) (71 mg) (95 mg) (180 mg)
Sephadex LH-20
(CHCl3 - MeOH  = 1:1)
Fr. 4-1-1 Fr. 4-1-2
(28 mg) (17 mg)
MPLC, NP Column 
(CHCl3 - MeOH = 98:2)
Fr. 4-1-2-1 Fr. 4-1-2-2
(6.75 mg) (5.5 mg)
Compoun 10 (5.5 mg)
Fr.4-6-1 Fr.4-6-2 Fr.4-6-3 Fr.4-6-4
Silica Gel C.C. 
(CHCl3 - MeOH = 10:0 ~  0:10)
Purified on Sephadex LH-20
(CHCl3 - MeOH = 1:1)
(15 mg) (20 mg) (17 mg)(40 mg)
Fr.4-6-3
(26.7 mg)








Silica gel C.C. 
(CHCl3 - MeOH = 10:0 ~ 0:10)
Fr. 4-3-1 Fr.4-3-2 Fr.4-3-3 Fr.4-3-4
(73 mg) (3 mg) (13 mg) (14 mg)
Fr. 4-3 (105 mg)
Sephadex LH-20,
(100% MeOH)
Fr. 4-3-1-1 Fr. 4-3-1-2
(4 mg) (57 mg)
Silica gel C.C. 
(CHCl3 - MeOH =  99:1)
Fr. 4-3-1-2-3
(14 mg)
Fr.4-3-3-1 Fr.4-3-3-2 Fr.4-3-3-3 Fr.4-3-3-4
Fr. 4-3-1-3
Compound 11 (4 mg)
Fr. 4-3-1-2-1 Fr. 4-3-1-2-2
(37 mg) (4 mg)
(10 mg)




(1.2 mg) (1.5 mg) (2.4 mg) (4 mg) (1.7 mg) (1.1 mg)
Compound 13 (4 mg) Compound 14 (1.7 mg)
 
Chart 8 
Silica gel C.C. 
(CHCl3 -  MeOH = 10:0 ~ 0:10)
Fr. 5-1 Fr.5-2 Fr.5-4 Fr.5-7
(20 mg) (15 mg) (32 mg) (108 mg)




(30 mg) (13 mg) (100 mg)
Fr.5-5-1 Fr.5-5-2




Compound 15 (13 mg)
(13 mg) (4 mg) (7 mg)
Sephadex LH-20







Scheme (D):  Isolation of the main constituents from 60 % MeOH 
fraction of the culture broth of Staphylococcus sp. (No. P-100826-4-6)   




60% MeOH Fraction (14 g)
Dissolved in mixture of
(CHCl3 - MeOH - H2O =  5:5:1)
Soluble part
  (11.4 g)
Insoluble part
     (2.6 g)
Sephadex LH-20 
(CHCl3 - MeOH - H2O = 5:5:1)
Fr.1 Fr.2 Fr.4 Fr.5 Fr.6Fr.3
(6.7 g) (1.3 g) ( 1.1 g) (540 mg) (620 mg) (1.1 g)
Silica gel C.C.  
(CHCl3 - MeOH, 10:0 ~  0:10)
Fr. 3-1 Fr.3-2 Fr.3-3 Fr.3-4 Fr.3-5 Fr.3-6 Fr.3-7
(120 mg) (64 mg) (186 mg) (140 mg) (76 mg) (80 mg) (420 mg)
ODS Column
(H2O - MeOH = 7:3 )
Fr.3-3-1
 ( 160 mg)
Fr.3-3-2
 ( 10 mg)
Fr.3-3-3
  (15 mg)
ODS Column
(H2O - MeOH = 8:2 )
Fr.3-3-1-1
 ( 60 mg)
Fr.3-3-1-2
 ( 70 mg)
Fr.3-3-1-3
 ( 12 mg)
Fr.3-3-1-4
 ( 8 mg)
Crystalization from MeOH
Fr.3-7-1
  (340 mg)
Fr.3-7-2
  (80 mg)
Compound 15 (70 mg)









Fr. 3-2 (64 mg)
Silica gel C.C. 






  (10 mg)
Fr. 3-2-1-2
   (8 mg)
Fr. 3-2-1-3
   (8 mg)
Fr. 3-2-2-1
   (28 mg)
Fr. 3-2-2-2
   (4 mg)
Sephadex LH-20
(CHCl3 - MeOH = 1:1)
ODS Column 
(H2O - MeOH = 1:1)
Compound 1 (10 mg) Compound 17 (28 mg)
 
Chart 11 
Silica gel C.C. 
(CHCl3 - MeOH = 10:0 ~ 0:10)
Fr. 4-1 Fr.4-2 Fr.4-4 Fr.4-7
(18 mg) (77 mg) (20mg) (240 mg)




(7 mg) (8 mg) (138 mg)
Fr.4-8-1 Fr.4-8-3
(180 mg) (53 mg)
Fr.4-8-1-1 Fr.4-8-1-2
Silica gel C.C. (FL 60D)
(CHCl3 - MeOH = 85:15 )
Compound 19 (47 mg)
(73 mg) (4 mg)
ODS Column




































































































Fig. 5. Structures of known compounds isolated from 100% MeOH   























Fig. 6. Structures of known compounds isolated from 60% MeOH   





2.2. Structure Elucidation of the New Compounds Isolated from the 
Culture Broth of Staphylococcus sp. (No. P-100826-4-6). 
2.2.1. Structure Elucidation of Compound 3. 
      Compound 3 was obtained as a white amorphous powder. The 
molecular formula was assigned as C11H19N2O3 by HR-FAB-MS (m/z 
227.1396 [M+H] +, calcd 227.1391, ∆ + 0.5 mmu), indicating 4 degrees of 
unsaturation. The IR spectrum of 3 suggested the presence of a hydroxyl 
and/or (NH) groups (3229 cm-1) and amide carbonyl groups (1699 cm-1 
and 1652 cm-1). The 1H-NMR spectrum showed signals for an isobutyl 
group [δH 0.79 (3H, t, J= 7.5 Hz, H-12), 1.20 (3H, d, J= 6.8 Hz, H-13), 
1.37, 1.93 (each1H, m, H-11) and 2.51 (1H, m, H-10)] in addition to an 
amide proton [δH 9.54 (1H, brs, H-8)] (Table 2, Fig. 7).  
      The 13C-NMR spectrum displayed 11 carbon signals, including two 
methyl carbons [δC 11.0 (C-12), 16.0 (C-13)], three methylene carbons 
[δC 19.9 (C-4), 25.8 (C-11), 38.1(C-5)], one methylene carbon bearing 
nitrogen [δC 45.9 (C-3)], one methine carbon [δC 40.1 (C-10)], one 
methine carbon bearing nitrogen [δC 63.0 (C-9)], one quaternary carbon 
bearing oxygen [δC 87.4 (C-6)] and two carbonyl carbons [δC 167.4 (C-1), 
169.5 (C-7)] (Table 2, Fig. 8).  
      These data together with degree of unsaturation revealed that 3 
contained two rings in the molecule, thus 3 was found to have a bicyclic 
skeleton. Analysis of 1H-1H COSY spectrum of 3 showed extended 1H-1H 
spin system from H-9 to H3-12 via H-10 and H-11, as well as a vicinal 
correlation from H-10 to H3-13, in addition to 1H-1H COSY correlations 
of H-3 – H-5 (Fig. 9, 11). The hetero nuclear multiple bond correlation 
(HMBC) of NH-8 to C-1 and C-10 were observed, as well as H3-13 to C-




δ1.20 (3H, d, 6.8 Hz)
δ0.79 (3H, t, 7.5 Hz)








































































































       In addition to the correlation of H-12 to C-10 and C-11, H-9 and NH-
8 to C-1 carbonyl, giving rise to an isoleucine moiety (b) (Fig. 10, 11), 
Moreover HMBC correlations of H-5 to C-3, C-6, and C-4 indicated the 
presence of proline moiety (a). The connectivity of these two rings was 
revealed by HMBC correlation of NH-8 to C-6, C-1 and C-10 (Fig. 11).   
      The relative stereochemistry of C-6 and C-9 of 3 was confirmed on 
the basis of comparing the 13C- NMR data of 3 with those of known 
compound, notoamide M and other known compounds containing α-
hydroxyproline moiety. (59, 66, 72-74) Because the chemical chifts of C-3, C-
4, C-5, C-6 and C-7 showed the same data with those of notoamide M 
and cyclo (D-6-Hpro-L-Phe) (Fig. 12), the relative stereochemistry of C-6 
and C-9 as shown in Figure 13. The absolute configuration of the amino 
acid of 3 was determined by acid hydrolysis and Marfey’s method, (75) 
using standard amino acids. The absolute configuration of the isoleucine 
was determined as D-form Thus; the absolute configuration was defined 




















































Table 2: 1H-(500 MHz) and 13C-NMR (125 MHz) data of compound 3 in 
pyridine-d5a 
No. 3  
ᵟH  ᵟC 
1 - 167.4 
2 - - 
3 3.83 (2H, m) 45.9 
4 1.76 (1H, m) 
2.19 (1H, m) 
19.9 
5 2.24 (1H, ddd, J= 12.8, 12.2, 7.3 Hz) 
2.57 (1H, dd, J= 12.8, 5.5 Hz) 
38.1 
6 - 87.4 
7 - 169.5 
8-NH 9.54 (1H, brs) - 
9 4.01 (1H, dd, J= 8.0, 4.1 Hz) 63.0 
10 2.51 (1H, m) 40.1 
11 1.37 (1H, m) 
1.93 (1H, m) 
25.8 
12 0.79 (3H, t, J= 7.5 Hz) 11.0 
13 1.20 (3H, d, J= 6.8 Hz) 16.0 
 
aSpectra were acquired at 23 ºC. Chemical shifts were given in δ (ppm) and 
referenced to internal solvent for pyridine-d5 at 7.19 (δH) and 123.5 (δC) ppm. 
 












2.2.2. Structure Elucidation of Compound 4. 
      Compound 4 was obtained as a white amorphous powder. The 
molecular formula was assigned as C10H17N2O3 by HR-FAB-MS (m/z 
213.1266 [M+H] +, calcd 213.1240, ∆+2.6 mmu), indicating 4 degrees of 
unsaturation. The IR spectrum of 4 suggested the presence of a hydroxyl 
group (3244 cm-1) and amide carbonyl groups (1700 cm-1 and 1652 cm-1).   
      The 1H-NMR spectrum showed signals for an isopropyl group [δH 
1.12 (3H, d, J= 7.1 Hz, H-12), 1.16 (3H, d, J= 7.1 Hz, H-11), 2.83 (1H, 
dsept, J= 7.1, 4.6 Hz, H-10)] and an amide proton [δH 8.73 (1H, brs, H-
8)] (Table 3, Fig. 14). The 13C-NMR spectrum displayed 10 carbon 
signals, including two methyl carbons [δC 16.8 (C-12), 18.8 (C-11)], two 
methylene carbons [δC 20.5 (C-4), 37.1 (C-5)], one methylene carbon 
bearing nitrogen [δC 45.3 (C-3)], one methine carbon [δC 29.2 (C-10)], 
one methine carbon bearing nitrogen [δC 60.7 (C-9)], one quaternary 
carbon bearing oxygen [δC 88.0 (C-6)] and two carbonyl carbons [δC 
167.5 (C-1), 170.4 (C-7)] (Table 3, Fig. 15).  
      These data showed the presence of two amide groups and thus 4 was 
found to have a bicyclic skeleton in the same manner as 3. Detailed 
analysis of 2D NMR spectral data such as COSY and HMBC spectrum 
showed the presence of two partial structures including α-hydroxy proline 
moiety (a) and valine moiety (b) (Fig. 16, 17 and 18). Furthermore, the 
connectivity of these partial structures was revealed by HMBC 
correlation of NH-8 to C-6 and C-1, and H-5 to C-7.  
      The 1H- and 13C-NMR signals of compound 4 and previously isolated 
compound bacillusamide B (59) showed close correspondence, except the 
chemical shift of H-9 [4: δH 4.50 (1H, d, J= 2.5 Hz), bacillusamide B: 




δ1.16 (3H, d, 7.1 Hz)
δ1.12 (3H, d, 7.1 Hz)
δ4.50 (1H, d, 2.5 Hz)
δ3.91 
(1H, ddd, 14.2, 9.4, 2.5 Hz)
δ3.69 
(1H, ddd, 14.2, 9.4, 2.5 Hz)
δ2.83




(1H, dd, 13.0, 5.7 Hz)
δ2.45































































Fig. 16. 1H-1H COSY spectrum of compound 4 (500 MHz, pyridine-d5).
C7
C1
C6 C9 C3 C5
















Table 3:  1H-(500 MHz) and 13C-NMR (125 MHz) data of compound 4 
and bacillusamide B   in pyridine-d5a. 
 
 
No. 4 bacillusamide B 
   ᵟH                                                  ᵟC                                                                               ᵟH                              ᵟC                                                                                  
1 - 167.5 - 167.5 
2 - - - - 
3 3.69 (1H, ddd, J= 14.2, 9.4, 2.5 Hz) 
3.91 (1H, ddd, J= 14.2, 9.4, 2.5 Hz) 
45.3 3.82 (2H, t, J= 9.2Hz) 45.8 
4 1.78 (1H, m) 
2.18 (1H, m) 
20.6 1.74 (1H, m) 
2.23 (1H, m) 
19.8 
5 2.45 (1H, ddd, J= 11.9, 8.2, 3.9 Hz) 
2.53 (1H, dd, J= 13.0, 5.7 Hz) 
37.1 2.27 (1H, m) 
2.56 (1H, m) 
37.9 
6 - 88.0 - 87.3 
7 - 170.4 - 169.5 
8 8.73 (1H, brs) - 9.58 (1H, m) - 
9 4.50 (1H, d, J= 2.5 Hz) 60.7 3.87 (1H, dd, J= 6.8, 4.0 Hz) 64.3 
10 2.83 (1H, dsept,  J= 7.1, 4.6 Hz) 29.2 2.69 (1H, m) 33.8 
11 1.16 (3H, d, J= 7.1 Hz) 18.8 1.18 (3H, d, J= 6.8 Hz) 19.9 
12 1.12 (3H, d, J= 7.1 Hz) 16.8 1.12 (3H, d, J= 6.8 Hz) 19.6 
 
aSpectra were acquired at 23 ºC. Chemical shifts were given in δ (ppm) and 















      This fact indicated that 4 was diastereoisomer to bacillusamide 
B (59) at position C-9 as shown in Figure 19. The absolute 
configuration of the amino acid of 4 was determined by acid 
hydrolysis and Marfey’s method, (75) using standard amino acids. 
The absolute configuration of the valine was determined as L-form 
Thus; the absolute configuration was defined as 6 R, 9 S as shown 
in Figure 20. 
     From the aforementioned spectroscopic studies (IR, 1H-NMR, 
13C-NMR, 1H-1H COSY, HMBC, HSQC and HR-FAB-MS) it 





























2.2.3. Structure Elucidation of Compound 9. 
      Compound 9 was obtained as a white amorphous powder by a multi-
step chromatography procedure from the fermentation broth of the marine 
microorganism Staphylococcus sp. (No.P-100826-4-6). It gave a [M+H]+ 
peak in the (HR-FAB-MS) at m/z 994.6538 (calcd for C49H88N9O12, 
994.6552, ∆–1.4 mmu) indicating 11 degrees of unsaturation. The intense 
absorptions between 1600‒1700 cm-1 and between 3100‒3400 cm-1 in the 
IR spectrum suggested the presence of the amide C=O and NH groups 
respectively. Compound 9 showed negative to ninhydrin but positive after 
hydrolysis with 6 M HCl, indicating that 9 contain cyclopeptide. (76)  
      The 1H-NMR spectrum of 9 revealed 8 methine protons (C-H) [δH 
5.64, 5.64, 5.05, 4.98, 4.90, 4.83, 4.70, 4.62, 1H each], 7 amide protons 
NH-C=O [δH 9.58, 9.48, 9.20, 8.91, 8.83, 8.75, 8.41, partly overlapped, 
1H each], long methylene chain centered at δH 1.22 (12H, brs), 10 methyl 
protons, among them 9 methyl doublet [δH 1.17, 1.13, 1.02, 0.96, 0.95, 
0.93, 0.92, 0.85, 3H each, d, J=6.6 Hz] and one methyl triplet [δH 0.81, 
3H, t, J=6.9 Hz] (Table 5, Fig. 21) .  
      The 13C-NMR spectrum showed 49 carbon signals, attributable to 10 
carbonyl carbons [δC 175.6, 175.5, 174.8, 173,8, 173.6, 173.4, 172.5, 
172.4, 172.0, 171.7], 7 methine carbons bearing nitrogen [δC 61.0, 55.0, 
53.50, 52.7, 52.5, 52.5, 51.5], one methine carbons bearing oxygen [δC 
72.50], 5 methine carbon [δC  28.5, 25.4, 25.3, 25.1, 24.9] 10 methyl 
carbons [δC 23.6, 23.4, 23.2, 22.8, 21.8, 21.5, 21.5, 19.5, 18.7, 14.4], 16 
methylene carbons (Table 5, Fig. 22). We could easily deduce that 9 was 
cyclic peptide composed of 1 Val, 3 Leu, 1 Asn, 1 Asp, 1 A2pr residues 






































Fig. 24. 1H-1H COSY spectrum of compound 9 (500 MHz, pyridine-d5). 
 














Fig. 26. NOESY Spectrum of






2H of A2Pr, F.A
 










COSY correlations, heteronuclear single-quantum correlation, 
heteronuclear multiple bond correlation and nuclear Overhauser 
enhancement spectroscopy as shown in (Fig. 23~27).  
      The amino acid sequence in 9 was determined by analysis of the 
NOESY and HMBC data of 9 as shown in (Fig. 27). NOESY correlation 
observed in 9 between amino acids methine protons and adjacent residue 
NH protons unambiguously identified the following seven amide bonds: 
Asp-CO/Leu1-NH (δH 4.83/8.41), Val-CO/Asp-NH (δH 4.70/8.83), Leu2-
CO/Val-NH (δH 4.98/9.48), Leu3-CO/Leu2-NH (δH 4.62/8.75), A2Pr-
CO/Leu3-NH (δH 5.64/9.58), Asn-CO/A2Pr-NH (δH 4.90/9.20), and 
HMTDA-CO/Asn-NH (δH 5.640/8.91).  
      The connectivity between HMTDA and Leu1 was also identified by 
NOESY correlation between α-methine proton HMTDA and NH proton 
of Leu1 (δH 5.64/8.41). These data together with HMBC correlation as 
shown in (Fig. 27) finally allowed us to establish the structure of 9 as 
cyclo (-A2Pr-Asn-HMTDA-Leu1-Asp-Val-Leu2-Leu3-). FAB-MS data of 
9 supported the amino acid sequence of compound 9 as shown in (Table 
4). The absolute configuration of the amino acids of 9 was determined by 
the crude hydrolysate with Marfey’s reagent (75) and HPLC analysis with 
co-injection of standard amino acids. The hydrolysate was identified to 
posess 3 L-Leu, 1 L-Val, 1 L-Asp.  
      The configuration of A2Pr and C-3 of HMTDA were proposed by 
cautions analysis of NOESY correlation spectra (Fig. 27). The NOESY 
correlation between α-proton (δH 5.64, m) of HMTDA and amide proton 
(δH 8.91, brs) of Asn, between amide proton (δH 8.91, brs) of Asn and α-
proton (δH 4.90, m) of Asn, between α-proton (δH 4.90, m) of Asn and 
amide proton (δH 9.20, brs) of A2Pr, between amide proton (δH 9.20, brs) 




of A2Pr and amide proton (δH 9.58, brs) of Leu3, between amide proton 
(δH 9.58, brs) of Leu3 and α-proton (δH 4.62, m) of Leu3, between α-
proton (δH 4.62, m) of Leu3 and amide proton (δH 8.75, brs) of Leu2, 
between amide proton (δH 8.75, brs) of Leu2 and α-proton (δH 4.98, q, J= 
7,9 Hz) of Leu2 between  α-proton (δH 4.98, q, J= 7,9 Hz) of Leu2 amide 
proton (δH 9.48, brs) of Val, between amide proton (δH 9.48, brs) of Val 
and α-proton (δH 4.70, t, J= 6.6 Hz) of Val, revealed that the 
configuration at A2Pr and C-3 of HMTDA have the configuration of L-




















































Table 4: (+) FAB-MS parent and fragment ions for compound 9. 
 
Leu2     Val       Asp      Leu1









      From the aforementioned spectroscopic studies (IR, 1H-NMR, 13C-
NMR, 1H-1H COSY, HMBC, HSQC, NOESY and HR-FAB-MS) it could 








































Table 5:  1H-(500 MHz) and 13C-NMR (125 MHz) data of compound 9 
in pyridine-d5a 
 
aSpectra were acquired at 23 ºC. Chemical shifts were given in δ (ppm) and 
referenced to internal solvent for pyridine-d5 at 7.19 (δH) and 123.5 (δC) ppm. 
                   9 
Position δH δC Position δH δC 
L- Leu1   L- Leu3   
1 - 173.4 1 - 174.8 
2 5.05 (1H, m) 52.7 2 4.62(1H, m) 52.5 
3 1.97 (1H, m) 
2.10 (1H, m) 
39.5 3 2.10 (2H, m) 40.0 
4 1.97 (1H, m) 24.9 4 1.97 (1H, m) 25.1 
5 0.91 (3H, d, J= 6.6 Hz 21.3 5 1.02 (3H, d, J= 6.6 Hz) 23.4 
6 0.85 (3H, d, J= 6.6 Hz) 22.8 6 0.95 (3H, d, J= 6.6 Hz) 21.5 
NH 8.41 (1H, brs)  NH 9.58 (1H, brs) - 
L-Asp   A2Pr   
1 - 172.0 1 - 173.8 
2 4.83 (1H, m) 53.5 2 5.64 (1H, m) 51.5 
3 1.97 (1H, m) 
2.67 (1H, m) 
33.7 3 3.62 (1H, dd, J=15.8, 8.8 Hz) 
3.40 (1H, dd, J=15.8, 4.8 Hz) 
37.3 
4  175.6 NH 9.20 (1H, brs) - 
NH 8.83 (1H, brs) - NH2 Not observed - 
L-Val   L-Asn   
1 - 172.5 1 - 173.6 
2 4.70 (1H, t, J= 6.6 Hz) 61.0 2 4.90 (1H, m) 55.0 
3 2.67 (1H, m) 28.5 3 2.67 (1H, m) 
2.90 (1H, m) 
35.0 
4 1.17 (3H, d, J= 6.6 Hz) 19.5 4 - 175.5 
5 1.13 (3H, d, J= 6.6 Hz) 18.7 NH 8.91 (1H, brs) - 
NH 9.48 (1H, brs) - NH2 Not observed - 
L- Leu2   HMTDA   
1 - 172.4 1 - 171.7 
2 4.98 (1H, q, J= 7,9 Hz) 52.5 2 2.94 (1H, m) 
2.90 (1H, m) 
43.0 
3 2.10 (2H, m) 39.6 3 5.64 (1H, m) 72.5 
4 1.97 (1H, m) 25.3 4 1.76 (2H, m) 42.6 
5 0.96 (3H, d, J= 6.6 Hz 23.2 5 1.40 (1H, m) 25.4 
6 0.92 (3H, d, J= 6.6 Hz) 21.8 5Me 0.93 (3H, d, J=6.6 Hz) 23.6 
NH 8.75 (1H, brs) - 6 1.29 (2H, m) 32.0 
   7-12 1.22 (12H, overlapped) 28.7-29.0 
   13 1.33 (2H, overlapped) 22.9 




2.2.4. Structure Elucidation of Compound 10. 
      Compound 10 was obtained as colorless solid. The molecular formula 
was assigned as C10H17N2O3S by HR-FAB-MS (m/z 245.0913 [M+H] +, 
calcd 245.0960, ∆ – 4.7 mmu), indicating 4 degrees of unsaturation. The 
EI-MS of 10 show the [M] + at m/z (rel.int. %) 244 (35%) and 
diagnostically important fragments at m/z 181 [M-SOCH3] + (60%), 154 
[M+-SOCH3-CH2-CH2-] (53%) and base beak at 70 (100 %) attributed to 
pyrrolidine ring of proline moiety (Fig. 34). The IR spectrum of 10 
displayed absorption bands attributed to an amide carbonyl groups (1697, 
1653 cm-1) and strong absorption band (1020 cm-1) suggesting the 
presence of a sulfoxide group. (77-78)  
      In the 1H-NMR spectrum, singlet methyl proton [δH 2.51 (3H, s, H-
13)] and one amino protons [δH 9.27 (1H, brs, H-8)] were observed 
(Table 6, Fig. 29). The 13C-NMR spectrum showed 10 carbon signals, 
attributable to one methyl carbon [δC 38.2 (C-13)], five methylene 
carbons [δC 22.9 (C-4), 23.5 (C-10), 28.5 (C-5), 45.5 (C-3), 49.7 (C-11)], 
two methine carbons [δC 54.7 (C-9), 59.5 (C-6)] and two carbonyl 
carbons [δC 165.9 (C-1), 170.7 (C-7)] (Table 6, Fig. 30). The 1H and 13C 
chemical shifts of C-13 of 10 (δH 2.51; δC 38.2) suggested the presence of 
sulfoxide group adjacent to this methyl group, (79) which was confirmed 
by the EI-MS fragment ions at m/z 181 [M-SOCH3] +.  
      These data together with degree of unsaturation revealed that 10 
contained two rings in the molecule, thus 10 was found to have a bicyclic 
skeleton.  Analysis of 1H-1H correlation spectroscopy (COSY) spectrum 
of 10 showed two proton spin systems, H3–H4–H5–H6 and NH–H9–H10–
H11 (Fig. 31, 36). The hetero nuclear multiple bond correlations (HMBC) 
of H-3 to C-5, H-6 to C-7, H-5 to C-7, H-13 to C-11,  H-11 to C-13, and 





















































































































Fig.  33. NOESY spectrum of compound 10 (500 MHz, pyridine-d5). 
 
      Moreover HMBC correlation of H-9 to C-1 was also observed. These 
data defined the presence of proline moiety (a) and 2-amino-4-
(methylsulfinyl) butanoic acid moiety (b) in 10 (Fig. 32, 36). The 
connectivity of these two moieties was revealed by HMBC correlation of 
NH-8 to C-6 and C-1, and H-10 to C-1 (Fig. 32, 35).  
      The most challenging task in the structure elucidation of 10 was the 
assignment of it’s configurationally pattern, since 10 contains three 
stereocenters one at sulfur and two at carbons (C-6 and C-9). The 
configuration of these stereocenters was determined by combination of 
1H-NMR, NOESY correlation, CD experiments and comparison with 
literature compounds. (59) The assignment of the absolute configuration at 
sulfur was achieved by CD studies. Mislow et al. have shown that a 
correlation exists between the absolute configuration of methyl alkyl 




strengths of appropriate Cotton effects. (80) In the absence of strongly 
perturbing groups, as in case alkyl allyl or diallyl sulfoxides, (81) a 
negative Cotton effect, centred at the absorption band near in the region 
220–230 nm, correlates with R configuration. This rule was found to still 
be applicable when the alkyl group itself is also chirals (82) as in 
compound (10). Therefore, by application of Mislow’s rule the R 
configuration could be assigned to the sulfur atom in 10 because negative 
Cotton effect at 218 nm was observed in its CD spectrum (Fig. 35).  
      The relative stereochemistry of C-6 and C-9 of 10 was determined by 
the nuclear Overhauser enhancement spectroscopy spectrum (Fig. 33, 
37). Correlation between H-6 with H-9 suggested that the two protons 
had same orientation as the diketopiperzine ring. This relative 
stereochemistry was confirmed on the basis of comparing the 1H- and 
13C-NMR data of 10 was those of known compound bacillusamide A. (59) 
Because the chemical shifts of H-6, H-9, C-6 and C-9 of 10 showed the 
same data with those of bacillusamide A, so the relative stereochemistry 
of C-6 and C-9 was determined as shown in Fig. 38. Thus, the absolute 
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Table 6: 1H-(500 MHz) and 13C-NMR (125 MHz) data of compound 10 in 
pyridine- d5a 
      From the aforementioned spectroscopic studies (IR, 1H-NMR, 13C-
NMR, 1H-1H COSY, HMBC, HSQC, NOESY, CD and HR-FAB-MS) it 






















     
Fig. 38. Structure of compound 10. 
No. 10 
ᵟH                                                                                           ᵟC 
1 - 165.9 
2 - - 
3 3.43 (1H, ddd, J=11.8, 8.8, 3.8 Hz) 
3.55 (1H, dt, J=8.0, 3.3, Hz) 
45.5 
4 1.57 (1H, m) 
1.65 (1H, m) 
22.9 
5 2.13 (1H, m) 
2.22 (1H, m) 
28.5 
6 4.16 (1H, t, J= 8 Hz)  59.5 
7 - 170.7 
8- NH 9.2(1H, brs) - 
9 4.36 (1H, t, J= 4.9 Hz) 54.7 
10 2.66 (2H, m) 23.5 
11 3.06 (1H, ddd, J=12.1, 7.4, 5.2 Hz) 49.7 




2.51 (3H, s) 
- 
38.2 
aSpectra were acquired at 23 ºC. Chemical shifts were given in δ (ppm) and 









aeruginosa, Aspergillus niger, Penicillium crustosum, Schizophyllum 
commune ， Trichophyton concentrieum ， Saccharomyces cerevisiae, 
Serratia marcescens subsp.  marcescens and Candida albicans  with 125 
µg/ disk, The results of antimicrobial activities were listed in (Table  8).  
 
2.3.1. Determination of Minimum Inhibitory Concentration (MIC) of   
Compound 10.  
      The MIC of compound 10 was measured according to macrobroth or 
tube-dilution method. (84-85) This procedure involved preparation two-fold 
dilutions of sample at (e.g. 100, 50, 25 and 12.5 µg/ml) in a liquid growth 
medium dispensed in test tubes. The sample containing tubes were 
inoculated with bacterial and fungal suspension then incubated at 37 ºC 
for Escherichia coli, Staphylococcus aureus subsp. aureus, 28 ºC for 
Bacillus subtilis subsp. subtilis, Pseudomonas aeruginsa, and Serratia 
marcescens subsp. Marcescens, and 25 ºC for Aspergillus niger, 
Penicillium crustosum, and Schizophyllum commune. The tubes were 
examined for visible growth as evidenced by turbidity. The lowest 
concentration that prevented growth represented minimum inhibitory 
concentration (MIC). The results of MIC of compound 10 were listed in 
(Table 7).  
 
Table 7:  Results of minimum inhibitory concentration MIC of 
compound 10. 
Tested microorganism               MIC (µg/ml) 
Aspergillus niger 50 
Penicillum crustosum 50 
Schizophyllum commune 50 
Staphylococcus aureus 100 
Pseudomonas aeruginosa 100 
Escherichia coli 100 
Bacillus subtilis inactive 
















Inhibition circle: －; < 8 mm, ±; 8 mm, ＋; < 8mm ~ < 10 mm, ++; ≧ 10 mm 
 
Antimicrobial activity test (125µg/disc) 
Microbial strains 1 2 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Bacillus subtillis  – – – – – – – – – – – – – – – – – 
Staphylococcus aureus  – – ± ± ± ± ± + – – – + + + – – – 
Serratia marcescens  – – – – – – – – – – – – – – – – – 
Escherichia coli – – ± ± ± ± ± + – – – + + + – – – 
Pseudomonas aeruginosa – – – – – – – + – – – – – – – – – 
Schizophyllum commune – – ± ± ± ± + ++ – – – + + + – – – 
Vivrio parahaemorytics – – – – – – – – – – – – – – – – – 
Aspergillus niger – – – – – – – ++ – – – – – – – – – 
Penicillium crustosum – – – – – – – ++ – – – – – – – – – 
Candida albicans – – – – – – – – – – – – – – – – – 
Saccharomyces cerevisiae – – – – – – – – – – – – – – – – – 
Trichophyton concentricum – – – – – – – – – – – – – – – – – 




3. Materials and Methods. 
3.1. Biological Materials. 
      Samples include marine bacteria isolated from Corallina officinalis 
Linneaus family Corallinaceae collected in Nagasaki Shitsu coast of 
Japan in 2010. For the isolation of bacteria, the scheme illustrated in (Fig. 
38) was used, a piece of the inner part of the plant of Corallina officinalis 
Linneaus was cut under sterile conditions, and inoculated on agar slants 
and incubated at 25 °C. A pure culture of the bacteria was prepared 
through repeated inoculation on fresh malt agar plates. The bacteria were 
then grown in 300 mL cultures and after a period of incubation, broth was 
extracted. The extracts were screened for antimicrobial activity and those 
exhibiting significant bioactivity were mass cultivated under the same 
growth conditions.  
      The marine bacterium was identified as Staphylococcus sp (No. P-
100826-4-6). The selected strain was scale up cultured at Laboratory of 
Garden for Medicinal plants, Graduated School of biomedical Sciences, 
Nagasaki University for chemical investigation at 25 °C on rotary shakers 
using seawater based medium. The fermentation broth (32L) was 
successively portioned with EtOAc to give EtOAc extract (5.2 g) and the 
aqueous layer subjected to Diaion HP-20 using H2O, 60% MeOH, 100% 
MeOH and acetone respectively to give 60% MeOH (28.3 g), 100% 
MeOH (8 g) and acetone (3.9 g) fractions respectively.  
  
3.2. Chemical Used  
3.2.1. General Laboratory Chemicals  
      Sulfuric acid, hydrochloric acid, dimethylsulfoxide (DMSO), 































Fig. 39. Bacterial collection, isolation, and cultivation scheme. 
Corallina offcinalis Lineaus Isolation of   pure bacteria 
Stocked cultured 
25 o C culured 
200 ml/sample 
Liquid cultured 
Added acetone, then 
concentrated 
Screening Bioassay 
Scale - up 
Aqueous suspension
extracted with EtOAc
aqueous layer EtOAc layer
1) dried





H2O, 60% MeOH, 100% MeOH, 










trifluroacetic acid (TFA), P-anisaldehyde, Nα-(5-f uoro-2,4dinitrophenyl)-
L-leucinamide (FDLA),  and n-Butanol. 
 
3.2.2 Chemicals for Culture Media. 
      Agar-agar, glucose, dextrose, polypeptone, Glucose, magnesium 
sulphate heptahydrate (MgSO4.7H2O), malt extract, potato sucrose agar, 
peptone, potassium dihydrogen phosphate (KH2PO4), sabouraud dextrose 
broth, sea water, distilled water, and yeast extract. 
 
3.2.3 Spray Reagents. 
      The reagents were stored in amber-colored bottles and kept 
refrigerated until use. TLC was used to monitor the identity of each of the 
fractions and the   qualitative purity of the isolated compounds. It was 
also utilize to optimize the solvent system that would be applied for 
column chromatography. 
1. Anisaldehyde/H2SO4 Spray Reagent 
2. 10% H2SO4 (v/v) in MeOH. 
2. Ninhydrin G.R. 
 
3. 4. Solvents. 
      The solvents used in this work were methanol, ethyl acetate, 
chloroform, n-hexane, acetonitrile, acetone, and water. All solvents were 
distilled prior to use and spectroscopic grades were used for spectroscopic 
experiment.  
3. 5. Equipment. 
      Portable ultraviolet lamp (254/365 nm), (Model UV GL-25, U.S.A.), 
Rotary evaporator, IR spectra were obtained with JASCO FT/IR-410 
spectrophotometres, circular dichroism (CD) spectra were recorded on a 




JASCO DIP-370 digital  polarimeter, 1H- and 13C-NMR, 1H-1H COSY, 
NOESY, HSQC and HMBC spectra  were recorded with a Unity plus 500 
spectrometer (varian Inc., U.S.A.)  operating at 500 MHz for 1H, and 125 
MHz for 13C respectively, FAB-MS were recorded on JMS DX-303 
spectrometer (JEOL Ltd., Japan), and m-nitrobenzyl alcohol or magic 
bullet as a matrix, preparative HPLC was peroformed on a Develosil C-
30-UG-5 (250 x 4.6  mm i.d nomura Chemical Co., Aichi, Japan) and a 
Wakosil-II 5sil-100 (150 x 4.6 mm “B” Wako pure chemical industries, 
Ltd, Japan) at flow rate  of 1.5 ml/min., equipied with a TOSOH RI-8020 
detector and a JASCO BIP-I HPLC pump, fraction collector, incubator 
shaker, autoclave, laminar air flow, medium pressure liquid 
chromatography (MPLC), analytical HPLC (Mightysil RP-18 (250 x 4.6 
mm i.d., Kanto Chemical Co., Inc.), petri dishes, parafilm, sonicator, 
antibiotic sensitivity discs, sterile falcon tube, oven, hot plate, and  
balance. 
 
3.6. Chromatographic Methods. 
3.6.1. Thin Layer Chromatography (TLC).  
      TLC was performed on precoated plates with Si-gel F254 (layer 
thickness 0.2 mm, Merck Ltd, Japan) as stationary phase. Liquid mobile 
phases were either semi-polar (CH2Cl2: MeOH; 9:1, v/v) or non polar 
(Hexane: EtOAc; 8:2, v/v). Reversed phase (RP) was used for polar 
fractions.  The TLCs were performed on precoated plates of C18  F254  
(layer thickness 0.25 mm, E. Merck, Darmstadt, Germany) as stationary  
phase. The mobile phase systems were MeOH: H2O; 3:7, 8:2 and 1:1 
(v/v). A one-dimensional ascending development technique was used to 
detect the constituents of an extract on TLC plate. Visual detection was 




depending on the group of compounds investigated. The separated 
compounds were also detected by spraying with a variety of chemical 
reagents previously described.   
 
 3.6.2. Column Chromatography.   
       In this study, three different kinds of columns were used.  The 
columns differed in their packing material used as stationary phase.  
- Normal phase column chromatography:  Si-gel F254 with a particle size 
of 0.0045 – 0.075 mm or 230-400 mesh (Wako pure industries Ltd 
Company) was used as stationary phase. Combinations of organic 
solvents such as n-hexane, CHCl3, and MeOH were used by step gradient 
or isocratic elution.   
 - Reversed phase column chromatography: RP-18 column was eluted 
step gradient starting with 60% MeOH in water which was increased to 
100 % MeOH.  For separation of fractions of low quantities a prepacked 
lobar column was used.       
- Gel permeation chromatography on Sephadex LH-20 material: this 
technique was applied for separations of mixtures containing different 
sizes of molecules. The gel material was suspended in an appropriate 
solvent and packed into a glass column. The column height was 100-120 
cm had to be equilibrated for 12-24 hrs before sample was loaded.  
 
3.6.3. Semi-Preparative HPLC.  
       Semi-preparative HPLC was used for the purification of the isolated 
compounds from complex and nearly pure fractions.  Each injection was 
concentrated to 3 mg/100 µl and the maximum injection volume was 100 






 3.6.4. Medium Pressure Liquid Chromatography (MPLC).  
      Medium Pressure Liquid Chromatography (MPLC) was introduced in 
1979 for separation of diateromethic oxasoline. The technique inquires a 
pressure of 50-105 bars, which properly separates larger amount of 
samples (100 mg – 100 g).  The separation efficiency depends on the 
mixture complexicity, solvent combination, and the pressure introduced.     
 
3.6.5. Analytical HPLC.  
      Analytical HPLC was used for identification of the constituents in the 
fractions and for checking the degree of purity of isolated compounds.  
Different systems were used, each injection was concentrated to 10µ /ml 
and the maximum injection volume was 10 µl.  The flow rate was set to 
1.0 ml/min.  Detection was performed under UV detector L-4000H and 
L-3350 RI detector using L-6200 intelligent pump. 
 
3.7. Structure Elucidation of the Isolated Secondary Metabolites. 
3.7.1. Mass Spectrometry (MS). 
      Mass spectra were measured by EI-, and FAB- FAB-MS on JMS DX-
303 spectrometer (JEOL Ltd., Japan), and m-nitrobenzyl alcohol or 
Magic bullet as a matrix measurements were done by Mr. N. Yamaguchi 
of the scientific support section of joint research center, Nagasaki 
University. 
 
3.7.2. Nuclear Magnetic Resonance Spectroscopy (NMR). 
      NMR measurements were done by Mr. M. Inada of the Scientific 
Support Section of joint Research Center, Nagasaki University. 1H- and 
13C-NMR, 1H-1H COSY, NOESY, HSQC and HMBC spectra were 
recorded with a Unity plus 500 spectrometer (Varian Inc., U.S.A.) 




300, ARX 400 or AVANCE DMX 600 NMR spectrometers. All 1D and 
2D. Spectra were obtained using the standard Jeol software. This sample 
is dissolved in a deuterated solvent (i.e. pyridine-d5, CDCl3, MeOD, and 
D2O), the choice of which is dependent on the solubility of the sample. 
Solvent signals at 3.30 ppm and 49.0 ppm (CD3OD) ; at 7.19, 7.55, 8.71 
ppm and 123.5, 135.5, 149.9 ppm (pyridine-d5); 7.26 ppm and 77 ppm for 
CDCl3 and 4.67 ppm  were considered as internal standard (reference 
signal). The observed chemical shift (δ) values were given in ppm and the 
coupling constants (J) in Hz. 
3.7.3. Infrared Spectroscopy (IR). 
      Infrared spectra were recorded at the Department Chemistry of 
Natural Product, Graduated School of Biomedical Sciences, and Nagasaki 
University. Spectra were obtained with JASCO FT/IR-410 
spectrophotometres.  
 
3.7.4. Circular Dichroism (CD). 
      CD spectrum was measured with a JASCO N-370 digital polarimeter. 
CD is a measurement of the difference in the absorbance by a chiral 
molecule of left and right circularly polarized light. CD curves are plots 
of ∆ε against the wavelength. 
  
3.7.5. Optical Activity. 
      Optical rotation was measured with a JASCO DIP-370 digital 











                                                    
where α = the measured angle of rotation in degrees, 
l = the length in dm of the polarimeter tube, 
c = the concentration of the substance expressed in g/100 mL of the 
solution. 
 
3.8. Protocol Advanced Marfey’s Method 
(Peptide hydrolysis): 
1. Take a minimum of 0.5 mg of peptide in a small glass vial with metal 
screw-top.  
2. Add 0.5 mL of 6 N HCl  
3. Incubate for 16 hours at 110 ºC  
4. Dry hydrolysed peptide under N2 flow until dryness  
(Marfey reaction):  
5. Add 50 µL pure water.    
6. Add 40 µL of 1 M NaHCO3  
7. Add 100 µl of 1% L-FDLA (or L-FDAA, both are Marfey reagent) 
(stock solution, 1 mg/100 µL of acetone).  
8. Incubate at 70 ºC for 40 minutes (reaction of Marfey reagent and 
amino acid residues).  
9. Cool at room temperature and add 20 µL 1N HCl in order to stop the 
reaction  
10. Dry under N2 flow and The residue was dissolved in H2O/CH3CN 





developing an effective general bioassay might be simply to screen for 
substances that are toxic to zoologic systems. Once such substances have 
isolated, a battery of specific and more sophisticated bioassays could then 
be employed. 
  
 3.9.1. Antimicrobial Activity. 
      Crude extracts and pure compounds were tested for activity against 
the following standard strains: gram positive bacteria such as Bacillus 
subtilis subsp. subtilis, Staphylococcus aureus subsp aureus, gram 
negative bacteria such as Escherichia coli, Serratia  marcescens subsp．
marcescens and Pseudomonas aeruginsa, fungi such as Aspergillus niger, 
Penicillium crustosum, Schizophyllum commune, Trichophyton 
concentrieum,  Saccharomyces cerevisiae,  and candida  albicans.    
      The paper disc for the antimicrobial test was prepared by taking 
aliquotes of 1 ml each of the different extracts in the separate eppendorf 
tubes. The sterilized paper disc prepared from the Whatman paper 
(diameter = 8 mm) were dipped in the extracts for 1 hr. After incubation, 
the paper discs were incubated in the oven at 45ºC overnight to evaporate 
the solvent from the paper disc. The antimicrobial activity of the test 
agents was determined by measuring the diameter of zone of inhibition 
expressed in mm.  
      For determination of the minimum inhibitory concentration (MIC), 
macrobroth or tube-dilution method. This procedure involved preparation 
two-fold dilutions of sample at (e.g. 100, 50, 25 and 12.5 µg/ml) in a 
liquid growth medium dispensed in test tubes. The sample containing 
tubes were inoculated with bacterial and fungal suspension then 
incubated at 37 ºC for Escherichia coli, Staphylococcus aureus subsp. 




aeruginsa, and Serratia marcescens subsp. marcescens and 25 ºC for 
Aspergillus niger, Penicillium crustosum, and Schizophyllum commune. 
The tubes were examined for visible growth as evidenced by turbidity. 
The lowest concentration that prevented growth represented minimum 


























4. Spectroscopic Data of Known Compounds. 
 Compound (1) cyclo (-L-pro-L-val-) (12 mg). 
       White amorphous powder. [α]D27 -72.8 (c=0.25, MeOH). Positive ion 
FAB-MS m/z 197.2 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 3.65 
(1H, dt, J= 11.8, 3.4 Hz, H-3), 3.50 (1H, dt, J= 11.8, 3.7 Hz, H-3), 1.75 
(2H, m, H-4), 2.15 (1H, m, H-5) 2.30 (1H, m, H-5), 4.20 (1H, t, J= 8.5 
Hz, H-6), 4.07 (1H, brs, H-9), 2.74 (1H, ddq, J= 2.4, 6.95, 7.15 Hz, H-
10), 1.19 (3H, J= 6.9 Hz, H-11) 1.15 (3H, J= 7.3 Hz, H-12). 13C-NMR 
(100 MHz, pyridine-d5) δ: 165.8 (C-1), 45.2 (C-3), 22.7 (C-4), 28.7 (C-5), 
59.2 (C-6), 170.8 (C-7), 60.7 (C-9), 28.8 (C-10), 18.8 (C-11), 16.8 (C-
12). 
 
Compound (2) bacillusamide B (10 mg). 
      Colorless amorphous powder. [α]D27 +41.8 (c=0.2, MeOH). Positive 
ion FAB-MS m/z 213.2 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 
3.77 (2H, t, J= 7.11 Hz, H-3), 2.20 (1H, m, H-4), 1.70 (1H, m, H-4), 2.58 
(1H, m, H-5), 2.35 (1H, m, H-5) , 3.90 (1H, dd, J= 7.8, 4.2 Hz, H-9), 
2.71 (1H, m, H-10), 1.19 (3H, J= 6.8 Hz, H-11), 1.12 (3H, J= 6.8 Hz, H-
12). 13C-NMR (100 MHz, pyridine) δ: 167.5 (C-1), 45.8 (C-3), 19.9 (C-
4), 36.7 (C-5), 87.4 (C-6), 169.6 (C-7), 64.4 (C-9), 33.9 (C-10), 19.9 (C-
11), 19.6 (C-12). 
 
Compound (5) Indole-3- carboxylic acid (5 mg). 
      Pale yellow solid. Positive ion FAB-MS m/z 162.1 [M+H] +. 1H-NMR 
(400 MHz, CD3OD) δ: 7.81 (1H, s, H-2)), 8.20 (1H, dd, J= 7.3, 2.2 Hz, 
H-4), 7.10 (2H, td, J= 7.1, 3.4 Hz, H-5, 6), 7.35 (1H, dd, J=7.3, 2.2 Hz, 
H-7). 13C-NMR (100 MHz, CD3OD) δ: 131.5 (C-2), 128.2 (C-3), 121.2 





Compound (6) 1, 5 Dideoxy-3-C-methyl arabinitol (86 mg). 
      Pale yellow oil. Positive ion FAB-MS m/z 135.1 [M+H] +. 1H-NMR 
(400 MHz, pyridine-d5) δ: 1.45 (3H, d, J= 6.4 Hz, H-1), 4.28 (1H, q, J= 
6.4 Hz, H-2), 4.28 (1H, q, J= 6.4 Hz, H-4), 1.45 (3H, d, J= 6.4 Hz, H-5), 
1.28 (3H, s, H-6). 13C-NMR (100 MHz, pyridine-d5) δ: 18.4 (C-1), 71.4 
(C-2), 76.6 (C-3), 71.4 (C-4), 18.4 (C-5), 18.4 (C-6). 
 
Compound (7) Thymine (8 mg). 
      White amorphous powder. Positive ion FAB-MS m/z 127.1 [M+H] +. 
1H-NMR (400 MHz, pyridine-d5) δ: 7.25 (1H, s, H-6), 1.93 (3H, s, H-7). 
13C-NMR (100 MHz, pyridine-d5) δ: 166.9 (C-2), 153.2 (C-4), 108.8 (C-
5), 137.8 (C-5), 12.4(C-7). 
 
Compound (8) Uracil (31 mg). 
      White amorphous powder. Positive ion FAB-MS m/z 113.2 [M+H] +. 
1H-NMR (400 MHz, pyridine-d5) δ: 5.77 (1H, d, J= 7.6, Hz, H-5), 7.55 
(1H, d, J= 7.6, Hz, H-6). 13C-NMR (100 MHz, pyridine-d5) δ: 152.9 (C-
2), 165.9 (C-4), 100.9 (C-5), 142 (C-5). 
 
Compound (11) cyclo (-L-pro-L-leu-) (4 mg). 
       Colorless amorphous solid. [α]D30 -20.4 (c=0.2, MeOH). Positive ion 
FAB-MS m/z 211.2 [M+H]+. 1H-NMR (400 MHz, pyridine-d5) δ: 3.58 
(1H, m, H-3), 3.42 (1H, m, H-3), 2.10 (1H, m, H-4), 1.82 (1H, m, H-4), 
4.20 (1H, t, J= 7.6 Hz, H-6), 2.25 (2H, m, H-5), 4.20 (1H, t, J= 7.6 Hz, 
H-9), 1.75 (1H, m, H-10), 1.26 (1H, m, H-10), 1.74 (1H, m, H-11), 0.92 
(3H, J= 6.5 Hz, H-12) 0.90 (3H, J= 6.5 Hz, H-13). 13C-NMR (100 MHz, 
pyridine-d5) δ: 167.1(C-1), 45.5 (C-3), 23.1 (C-4), 28.4 (C-5), 59.5 (C-6), 





Compound (12) cyclo (-L-pro-L-phe-) (37 mg). 
      White amorphous solid. [α]D27 -67.8 (c=0.65, MeOH). Positive ion 
FAB-MS m/z 245.2 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 3.62 
(2H, m, H-3), 1.56 (2H, m, H-4), 2.13 (1H, m, H-5), 1.79 (1H, m, H-5), 
4.20 (1H, t, J= 6.5 Hz, H-6), 4.6 (1H, t, J = 5.2 Hz, H-9), 3.35 (2H, m, H-
10), 7.26 (2H, m, H-12, 16), 7.48 (2H, m, H-13,15), 7.12 (1H, 
overlapped, H-14). 13C-NMR (100 MHz, pyridine-d5) δ: 165.1 (C-1), 45.4 
(C-3), 22.4 (C-4), 28.1 (C-5), 59.1 (C-6), 169.4 (C-7), 56.2 (C-9), 36.8 
(C-10), 135.9 (C-11), 129.1 (C-12), 129.2 (C-13), 127.5 (C-14), 129.2 (C-
15), 129.1, (C-16). 
 
Compound (13) cyclo (-L-pro-D-phe-) (4 mg). 
      Colorless amorphous solid. [α]D27 + 0.72 (c=0.15, MeOH), Positive 
ion FAB-MS m/z 245.2 [M+H] +. 1H-NMR (500 MHz, pyridine-d5) δ: 
3.43 (2H, m, H-3), 1.63 (1H, m, H-4), 1.49 (1H, m, H-4), 2.17 (1H, m, H-
5), 1.89 (1H, m, H-5), 3.70 (1H, dd, J= 10.5, 6.8 Hz, H-6), 4.5 (1H, t, J = 
7.5 Hz, H-9), 3.26 (1H, dd, J= 13.5, 7.0 Hz, H-10), 3.21 (1H, dd, J= 
13.5, 7.08 Hz, H-10)), 7.22 (2H, d, J= 8.0 Hz, H-12, 16), 7.30 ((2H, t, J= 
6.0 Hz,  H-13,15), 7.24 (1H, t, J= 6.0 Hz, H-14). 13C-NMR (100 MHz, 
pyridine-d5) δ : 165.7 (C-1), 45.4 (C-3), 22.1 (C-4), 29.5 (C-5), 59.1 (C-
6), 169.4 (C-7), 58.3 (C-9), 40.8 (C-10), 137.2 (C-11), 130.5 (C-12), 
128.8 (C-13), 127.3 (C-14), 128.8 (C-15), 130.5, (C-16). 
 
Compound (14) cyclo (-D-Hypro-L-phe-) (1.7 mg). 
      Colorless amorphous solid. [α]D30 -24.4 (c=0.085, MeOH).  Positive 
ion FAB-MS m/z 261.21 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 
3.65 (2H, m, H-3), 1.70 (1H, m, H-4), 1.25 (1H, m, H-4), 2.25 (1H, m, H-
5), 2.14 (1H, m, H-5), 3.90 (1H, dd, J = 8.9, 3.5 Hz, H-9), 3.35 (1H, dd, 




d, J= 7.3 Hz, H-12, 16), 7.24 (2H, t, J= 7.3 Hz,  H-13,15), 7.17 (1H, 
overlapped, H-14). 13C-NMR (100 MHz, pyridine-d5) δ: 167.2 (C-1), 45.4 
(C-3), 20.6 (C-4), 36.9 (C-5), 88.2 (C-6), 169.7 (C-7) 56.4 (C-9), 36.95 
(C-10), 137.8 (C-11), 130.0 (C-12), 128.8 (C-13), 127.0 (C-14), 128.8 (C-
15), 130.0 (C-16). 
 
Compound (15) cyclo (-L-pro-L-tyr-) (103 mg). 
      Colorless amorphous solid. [α]D30 -41.4 (c=0.5, MeOH). Positive ion 
FAB-MS m/z 261.21 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 3.52 
(1H, m, H-3), 3.32 (1H, m, H-3), 1.79 (1H, m, H-4), 1.25 (1H, m, H-4), 
2.25 (1H, m, H-5), 2.10 (1H, m, H-5), 4.03 (1H, dd, J= 10.9, 6.5 Hz, H-
6), 4.35 (1H, t, J = 6.7 Hz, H-9), 3.05 (2H, dd, J= 10.8, 4.6 Hz, H-10), 
6.7 (1H, d, J= 8.6 Hz, H-12, 16), 7.02 (2H, d, J= 8.6 Hz, H-13,15). 13C-
NMR (100 MHz, pyridine-d5) δ: 167.0 (C-1), 45.9 (C-3), 22.7 (C-4), 29.4 
(C-5), 57.9 (C-6), 170.8 (C-7), 60.0 (C-9), 37.7 (C-10), 127.7 (C-11), 
132.1 (C-12), 116.2 (C-13), 157.8 (C-14), 116.2 (C-15), 132.1 (C-16). 
 
Compound (16) Macrolactin B (26.7 mg). 
      Pale yellow amorphous solid. [α]D30 -7.4 (c=1.15, MeOH) positive ion 
FAB-MS m/z 587.3 [M+ Na] +. 1H-NMR (400 MHz, pyridine-d5) δ: 5.70 
(1H, d, J=11.5 Hz, H-2), 6.50 (1H, t, J=11.4 Hz, H-3), 7.2 (1H, dd, 
J=11.2, 15.2 Hz, H-4), 6.15 (1H, m, H-5), 2.47 (2H, m, H-6), 4.52 (1H, 
m, H-7), 5.65 (1H, m, H-8), 6.55 (1H, dd, J=11.6, 14.7 Hz, H-9), 6.17 
(1H, t, J=10.5 Hz, H-10), 5.57 (1H, m, H-11), 2.65 (2H, m, H-12), 3.95 
(1H, m, H-13), 1.45 (1H, m, H-14), 1.64 (1H, m, H-14), 4.68 (1H, m, H-
15), 5.50 (1H, m, H-16), 6.30 (1H, dd, J=10.2, 15.6 Hz, H-17), 6.10 (1H, 
dd, J=10.2, 15.5 Hz, H-18), 5.80 (1H, m, H-19), 2.05 (2H, m, H-20), 1.45 
(2H, m, H-21), 1.60 (2H, m, H-22), 4.96 (1H, q,  J=7.2 Hz H-23), 1.15 




3.80 (1H, m, H-3`) 3.54 (1H, m, H-4`), 3.18 (1H, m, H-5`) 3.89 (1H, dd, 
J=12, 2.5 Hz, H-6`), 3.81 (1H, dd, J=12, 7.2 Hz, H-6`). 13C-NMR (100 
MHz, pyridine-d5) δ: 168.05 (C-1), 119.4 (C-2), 145.8 (C-3), 130.9 (C-4), 
143.4 (C-5), 42.7 (C-6), 78.5 (C-7), 135.0 (C-8), 130.2 (C-9), 132.3 (C-
10), 130.8 (C-11), 38.7 (C-12), 70.1 (C-13), 45.4 (C-14), 70.6 (C-15), 
138.9 (C-16), 131.3 (C-17), 133.1 (C-18), 135.3 (C-19), 33.8 (C-20), 26.5 
(C-21), 36.9 (C-22), 73.7 (C-23), 21.7 (C-24), 103.3 (C-1`), 77.7 (C-2`), 
80.4 (C-3`), 72.2 (C-4`), 80.5 (C-5`), 64.7 (C-6`). 
 
Compound (17) cyclo (-L-pro-L-ala-) (28 mg). 
       Colourless solid. [α]D30 -22.2 (c=0.25, MeOH)Positive ion FAB-MS 
m/z 169.17 [M+H] +. 1H-NMR (300 MHz, CDCl3) δ: 6.50 (1H, brs, NH), 
3.55 (2H, m, H-3), 1.85-1.95 (2H, m,  H-4), 2.31 (1H, m, H-5), 2.11 (1H, 
m, H-5), 4.09 (1H, m, H-6), 4.09 (1H, m, H-9), 1.19 (3H, J= 6.9 Hz, H-
10). 13C-NMR (100 MHz, CDCl3) δ: 167.2 (C-1), 45.5 (C-3), 23.0 (C-4), 
28.55 (C-5), 51.4 (C-6), 170.7 (C-7), 59.6 (C-9), 15.9 (C-10). 
 
Compound (18) Phenylalanine (80 mg). 
      White amorphous powder. [α]D27 -35.3 (c=0.275, H2O) Positive ion 
FAB-MS m/z 166.2 [M+H] +. EI-MS m/z 165, other diagnostic fragments 
including, m/z 120 [M-COOH] +, m/z 103 [M-COONH3] +. 1H-NMR 
(300 MHz, D2O) δ : 3.94 (1H, t, J= 8.0 Hz, H-2), 3.08 (1H, dd, J= 8.2, 
14.2 Hz,  H-3), 3.22 (1H, dd, J= 8.2, 14.2 Hz,  H-3) 7.27 (2H, d, J= 6.9 
Hz, H-5, 9), 7.38 (2H, d, J = 7.4 Hz, H-9), 7.27 (1H, overlapped, H-7). 
3C-NMR (100 MHz, MeOH+H2O) δ: 174.9 (C-1), 56.9 (C-2), 37.4 (C-3), 







Compound (19) Tryptophan (40 mg). 
      White amorphous powder. [α]D27 -37.4 (c=0.14, H2O) Positive ion 
FAB-MS m/z 205.2 [M+H] +. 1H-NMR (400 MHz, pyridine-d5) δ: 3.49 
(1H, dd, J= 7.2, 2.7 Hz, H-2), 2.60 (1H, dd, J= 11.3, 2.7 Hz, H-3), 3.01 
(1H, dd, J= 11.3, 7.2 Hz, H-3), 6.60 (1H, s, H-5) 6.95 (1H, m, H-8), 6.44 
(1H, m, H-11), 6.10 (2H, m, H-9, 10), 10.5 (1H, brs, NH-6). 3C-NMR 
(100 MHz, pyridine-d5) δ: 173.5 (C-1), 56.1 (C-2), 27.6 (C-3), 109.3 (C-
4), 124.8 (C-5), 137.1 (C-7) 111.7 (C-8), 121.3 (C-9), 118.9 (C-10), 118.6 



















      The marine bacterium Staphylococcus sp. was obtained from 
Corallina officinalis Lineaus family Corallinaceae, collected in Nagasaki 
Shitsu coast of Japan in 2010. The strain was cultured at 25 ºC on rotary 
shakers using a seawater-based medium. The fermentation broth (32L) 
was successively partitioned with EtOAc to give EtOAc extract (5.2 g) 
and the aqueous layer was subjected to Diaion HP-20 using H2O, 60% 
MeOH, 100% MeOH and acetone to give 60% MeOH (28.3 g), 100% 
MeOH (8 g) and acetone (3.9 g) fractions. It has been observed that 
culture broth of Staphylococcus sp. (No. P-100826-4-6) derived from 
Corallina officinalis Lineaus family Corallinaceae, showed antifungal 
activity against Aspergillus niger, Penicillium crustosum and 
Schizophyllum commune. Therefore, we have researched the active 
constituents of this bacterium. As a result four new compounds, 3, 4, 9 
and 10 (Fig. 39) along with fifteen known compounds: cyclo (-L-pro-L-
val-) (1) bacillusamide B (2), indole-3-carboxylic acid (5), 1,3-dideoxy-3-
C-methyl arabinitol (6), thymine (7), uracil (8), (-L-pro-L-leu-) (11), cyclo 
(-L-pro-L-phe-) (12), cyclo (-L-pro-D-phe-) (13), cyclo (-D-6-Hypro-L-phe-
) (14), cyclo (-L-pro-L-tyr-) (15), macrolactin B (16), cyclo (-L-pro-L-ala-) 
(17), L-phenylalanine (18) and L-tryptophan (19). The antimicrobial 
activities of isolated compounds were tested by paper disk methods 
against Bacillus subtilis subsp. subtilis, Staphylococcus aureus subsp. 
aureus, Escherichia coli, Pseudomonas aeruginosa, Aspergillus niger, 
Penicillium crustosum, Schizophyllum commune ， Trichophyton 
concentrieum Saccharomyces cerevisiae, Serratia marcescens subsp.  
marcescens and Candida albicans  with 125 µg/ disk, as a result 
compounds 5~9, 14, 15 and 16 showed slightly antimicrobial against 




commune. Compound 10 exhibited a potent antifungal activity against 
Aspergillus niger, Penicillum crustosum and Schizophyllum commune, 
with MIC value 50 µg/ml. Compound 10 showed antibacterial activity 
against Staphylococcus aureus subsp aureus, Pseudomonas aeruginosa 
and Escherichia coli, with MIC value 100 µg/ml. Conversely, 10 was 
inactive against Bacillus subtilis subsp. subtilis and Serratia marcescens 
subsp. marcescens with MIC values higher than 100 µg/ml. The 
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